Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SYS6090 injection combination therapy in advanced or metastatic colorectal cancer
CTR20262910Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in colorectal cancer (CRC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Aug 2026; status: active.
02
Drugs
toripalimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20262910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262910.